Invest in

Drug-Patent Cliffs


Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 1.9%
19.7% Mylan N.V. MYL 9.2%
19.6% Taro Pharmaceutical Industries Ltd. TARO 14.5%
18.3% Dr. Reddy's Laboratories Ltd RDY 1.9%
11.4% The Medicines Company MDCO 60.3%
9.6% Abbott Laboratories ABT 17.9%
5.9% Akorn Inc. AKRX 15.4%
5.7% Mallinckrodt plc MNK 22.0%
5.3% Impax Laboratories Inc. IPXL 59.1%
2.3% Lannett Co Inc LCI 13.6%
1.5% Cambrex Corporation CBM 43.9%
0.7% Endo International PLC ENDP 74.8%

Quotes delayed 15 mins. Currently Feb 19, 2017 1:43:24 PM. Fields are marked with -- when data is unavailable.